sequencing-based diagnostics
Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar
The Seattle-based company saw 36 percent growth in its minimal residual disease business while making significant progress in curbing operating expenses.
Labcorp, Ultima Genomics Collaborate on NGS-Based Cancer Testing
Labcorp will use Ultima's UG100 sequencer and ppmSeq technology for minimal residual disease testing in patients with early-stage solid tumors.
Inocras, IMBdx Partner on Cancer Diagnostics in US
The partnership between the two firms with South Korean roots will bring IMBdx's sequencing-based liquid biopsy tests to the US market.
Adaptive Biotechnologies Expects Growth From FDA Panel MRD Vote, Cuts Staff by 7 Percent in Q1
Premium
Q1 revenues grew 11 percent year over year, to $41.9 million from $37.6 million, slightly less than the 12 percent increase the company had anticipated.
Adaptive Biotechnologies Shares Surge as FDA Panel Recommends MRD as Endpoint in Multiple Myeloma
Adaptive offers the FDA-cleared ClonoSeq assay for MRD testing in hematologic cancers, including multiple myeloma.